Core Insights - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][8] - The company announced the acceptance of abstracts for presentation at three upcoming congresses, highlighting its ongoing research and development efforts [1] Upcoming Presentations - At the C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, several presentations will focus on the clinical validation of biomarker assays, long-term prophylactic treatment with oral Deucrictibant, and patient experiences related to acquired angioedema [2] - The 2025 Eastern Allergy Conference and the EAACI Congress 2025 will also feature presentations on the long-term safety and efficacy of oral Deucrictibant for both prophylaxis and treatment of hereditary angioedema attacks [4][5] Research Focus - The presentations will cover various aspects of bradykinin-mediated angioedema, including clinical validation of novel biomarker assays, health-related quality of life improvements, and pharmacokinetics studies [2][3] - Pharvaris is currently evaluating the efficacy and safety of Deucrictibant in pivotal Phase 3 studies for both the prevention and on-demand treatment of HAE attacks [8]